Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best to use new bispecific antibodies, and expressed concern about looming cuts to science funding.